Skip to content Carb-X
Carb-X
Boston University
Mobile Menu Toggle navigation
  • Sign Up
  • Contact
  • Twitter
  • LinkedIn
Carb-X
Boston University
Boston University
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Omnibus Solicitation
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Applicant Questions
  • Resources
    • CARB-X Connect
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Media Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
  • Events
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Omnibus Solicitation
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Applicant Questions
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Media Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
  • Events
  • Contact
  • Legal

Portfolio Company

  • Portfolio
  • >
  • Gallery
Integrated Biotherapeutics

INTEGRATED BIOTHERAPEUTICS   Rockville, MD, USA
integratedbiotherapeutics.com

IBT-V02
MULTI-VALENT TOXOID VACCINE

Direct-Acting Large Molecule Therapeutic; Vaccine
IBT-V02 is the novel vaccine that consists of five components representing toxoids for seven Staphylococcus Aureus (SA) toxins. Due to cross-reactivity, these toxoids elicit protective responses to 12-15 SA toxins. Efficacy of IBT- V02 components have been shown in various mouse and rabbit models of infection. This is the first entirely non-surface antigen-based vaccine for SA disease. The studies to be performed under CARB-X support will complete the pre-clinical development of IBT-V02 and transitions the program to phase I clinical trial.

Current Development Stage: Pre-Clinical

CARB-X Investment: Initial investment of up to $168k with potential option payments up to $12.8m. In August 2019, CARB-X awarded an additional $1.62m to IBT to develop a freeze-dried version of the vaccine for use in developing nations where cold-storage systems are not available.

Initial CARB-X Investment Date: October 1, 2017

Read their Spotlight on Science

Carb-X

Led by Boston University

Copyright 2023

  • Contact
  • Careers
  • Site Credits
  • Legal
  • Twitter
  • LinkedIn

Copyright 2023